Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novartis Announces Positive CHMP Opinion For Kisqali
Novartis Gets CHMP Recommendation for Kisqali in Broader Population
Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali (ribociclib) for a broader patient population.
Novartis Announces Positive CHMP Opinion For Kisqali - Quick Facts
Novartis announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible
Novartis' Kisqali Cancer Drug Gets Positive Opinion From European Medicines Agency
The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human Use had adopted a positive opinion of Kisqali for the adjuvant treatment of adults with a type of early breast cancer,
Novartis receives positive CHMP opinion for its breast cancer treatment
BioSpace
23h
NJ Court Tosses Novartis’ Lawsuit Against Drug Negotiation Program in Latest Setback for Big Pharma
With Friday’s ruling by New Jersey District Judge Zahid Quraishi, Novartis joins a growing list of pharmaceutical companies ...
5d
Novartis loses latest bid to block generic version of blockbuster heart drug
Novartis has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by ...
FiercePharma
4d
Novartis falls short in legal effort to undo FDA approval of MSN's Entresto generic
As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss ...
FierceBiotech
4d
Novartis pays China's Baiyu $70M upfront, with $1.1B chaser, for small molecule cancer candidate
Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. | Novartis is paying ...
BioPharma Dive
1d
3B Pharmaceuticals Announces Option and Asset Purchase Agreement with Novartis for PSMA Radioligand Therapy Program
BP’s program includes a novel PSMA-binding molecule that may be a potential next-generation radioligand therapy (RLT) for prostate cancer and is currently being studied in two investigator-initiated ...
3d
PTC rebuffed again by EMA; Novartis licenses China-based biotech’s cancer drug
European regulators have for the fourth time issued a negative opinion on PTC's Translarna. Elsewhere, Amylyx read out data ...
FierceBiotech
7d
Novartis channels Gargamel, terminating midphase SMURF1 trial
Novartis has terminated a phase 2 trial of its SMURF1 inhibitor LTP001 in idiopathic pulmonary fibrosis (IPF) but will ...
4d
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move
Not every company is jumping onto the bandwagon and investing into weight loss drugs, however. One of the largest healthcare ...
3d
European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer
On Friday, Novartis AG (NYSE:NVS) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Kisqali
Food and Drug Administration
Baiyu
Ribociclib
Sacubitril/valsartan
Feedback